# GLP-1 Release by Rare Sugar D-Allulose Ameliorates Sucrose-Induced Obesity and Glucose Intolerance in Ovariectomized Mice

**Authors:** Kengo Iba, Miharu Kyo, Hirotaka Ishihara, Aki Nagao, Misaki Kawabe, Kento Ohbayashi, Toshihiko Yada, Yusaku Iwasaki

PMC · DOI: 10.3390/ijms27041651 · 2026-02-08

## TL;DR

D-allulose, a rare sugar, helps reduce obesity and glucose issues in mice lacking estrogen, possibly through GLP-1.

## Contribution

D-allulose improves metabolic dysfunction in ovariectomized mice via GLP-1, offering a safer alternative to hormone therapy.

## Key findings

- D-allulose reduced visceral fat and improved insulin resistance in sucrose-fed ovariectomized mice.
- GLP-1 receptor knockout mice showed reduced benefits from D-allulose, confirming GLP-1's role.
- Sucrose intake worsened obesity and glucose intolerance in ovariectomized mice.

## Abstract

Estrogen deficiency after menopause promotes visceral fat accumulation and insulin resistance, thereby increasing the risk of type 2 diabetes. Although hormone replacement therapy is partially effective, its use is limited by increased risks of cardiovascular disease and breast cancer, underscoring the need for safer preventive strategies. The rare sugar D-allulose has been reported to stimulate secretion of glucagon-like peptide-1 (GLP-1), a gut hormone, and improve obesity and glucose metabolism, suggesting its potential as a novel intervention for postmenopausal metabolic dysfunction. Here, we examined whether D-allulose improves obesity and glucose intolerance in a GLP-1-dependent manner under sucrose-fed conditions, using ovariectomized (OVX) female C57BL/6J mice as a model of menopause. OVX mice, but not sucrose-fed sham mice, developed exacerbated visceral obesity and glucose intolerance in response to dietary sucrose, despite similar total energy intake. Daily oral administration of D-allulose for two weeks significantly suppressed visceral fat accumulation, improved insulin resistance, and ameliorated glucose intolerance in sucrose-fed OVX mice. These beneficial effects were markedly attenuated in GLP-1 receptor knockout mice. Taken together, we found that sucrose intake after ovariectomy exacerbates visceral obesity and glucose intolerance, and that D-allulose effectively ameliorates these metabolic abnormalities. GLP-1-stimulating dietary components such as D-allulose may represent a safe and promising preventive strategy for metabolic dysfunction associated with menopause.

## Linked entities

- **Proteins:** GCG (glucagon)
- **Chemicals:** D-allulose (PubChem CID 441036), sucrose (PubChem CID 5988)
- **Diseases:** type 2 diabetes (MONDO:0005148), obesity (MONDO:0011122), glucose intolerance (MONDO:0001076)

## Full-text entities

- **Genes:** Glp1r (glucagon-like peptide 1 receptor) [NCBI Gene 14652] {aka GLP-1R, GLP1Rc}, Gcg (glucagon) [NCBI Gene 14526] {aka GLP-1, Glu, PPG}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}
- **Diseases:** Visceral Obesity (MESH:D056128), Glucose Intolerance (MESH:D018149), appetite (MESH:D001068), T2DM (MESH:D003924), inflammatory cytokines (MESH:D000080424), Estrogen (MESH:D056828), breast cancer (MESH:D001943), weight loss (MESH:D015431), Insulin Resistance (MESH:D007333), cardiovascular disease (MESH:D002318), gastrointestinal adverse effects (MESH:D005767), protein malnutrition (MESH:D044342), visceral adiposity (MESH:D007418), metabolic dysregulation (MESH:D021081), fat (MESH:D004620), Metabolic Dysfunction (MESH:D008659), hyperphagia (MESH:D006963), overweight (MESH:D050177), non-communicable diseases (MESH:D000073296), weight gain (MESH:D015430), weight regain (MESH:D055191), Obesity (MESH:D009765), glucose metabolic abnormalities (MESH:D044882), diabetes (MESH:D003920), protein insufficiency (MESH:D000309), injury to (MESH:D014947), metabolic syndrome (MESH:D024821), hyperglycemia (MESH:D006943)
- **Chemicals:** D-glucose (MESH:D005947), Sucrose (MESH:D013395), lipid (MESH:D008055), D-fructose (MESH:D005632), carbohydrates (MESH:D002241), AIN- (-), medetomidine (MESH:D020926), CE (MESH:D002563), Blood glucose (MESH:D001786), atipamezole (MESH:C050701), butorphanol (MESH:D002077), isoflurane (MESH:D007530), disaccharide (MESH:D004187), Water (MESH:D014867), Allulose (MESH:C003243), monosaccharides (MESH:D009005), 17beta-estradiol (MESH:D004958), sugar (MESH:D000073893), midazolam (MESH:D008874)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** /6J — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_W797), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940309/full.md

---
Source: https://tomesphere.com/paper/PMC12940309